文献速递前列腺癌

治疗患者而非仅治疗癌症:前列腺癌的治疗负担

Treating the patient and not just the cancer: therapeutic burden in prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-02-18

本文综述了转移性去势抵抗性前列腺癌(CRPC)患者治疗负担的多重因素,包括年龄、合并症、合并用药、二代雄激素受体抑制剂(ARI)的使用及经济困扰。结论强调需平衡治疗获益与潜在不良事件,尤其关注药物相互作用(DDI),并提倡以患者为中心的沟通、密切监测及运动与支持团体参与。

要点

  • CRPC患者治疗需平衡二代ARI获益与不良事件及DDI风险。
  • 合并症多药治疗常见,增加DDI潜在风险。
  • 以患者为中心沟通、密切监测和运动支持有助减轻治疗负担。

核心结论

  • 治疗CRPC需平衡二代ARI的治疗获益与潜在治疗出现的不良事件,后者可能因合并用药的DDI而复杂化。
  • 以患者为中心的沟通是减轻治疗负担的关键,医护人员可能受益于有效沟通培训。

研究设计与样本

  • 本文为综述,总结可能 contribuir 于CRPC患者治疗负担的多重因素。

主要发现

  • 持续雄激素剥夺与急性和长期不良效应相关,多数患者最终发展为CRPC。
  • 二代ARI(阿帕鲁胺、恩扎卢胺、达罗他胺)在无转移生存、无进展生存和总生存方面呈积极趋势。
  • 非转移性CRPC患者主要无症状,维持生活质量是处方治疗的主要目标。
  • 年龄相关合并症的多药治疗在该人群中常见,可能增加DDI潜在风险。

临床怎么用

  • 医护人员应密切且频繁监测患者治疗反应,以更好理解症状出现和加重。
  • 鼓励患者参与运动项目和健康信息与支持团体,以预防或减轻治疗负担的某些决定因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer (PC) is a leading cause of death in older men. Androgen deprivation therapy (ADT) is considered the standard-of-care for men with locally advanced disease. However, continuous androgen ablation is associated with acute and long-term adverse effects and most patients will eventually develop castration-resistant PC (CRPC). The recent approval of three, second-generation androgen receptor inhibitors (ARIs), apalutamide, enzalutamide, and darolutamide, has transformed the treatment landscape of PC. Treatment with these second-generation ARIs have produced positive trends in metastasis-free survival, progression-free survival, and overall survival. For patients with non-metastatic CRPC, who are mainly asymptomatic from their disease, maintaining quality of life is a major objective when prescribing therapy. Polypharmacy for age-related comorbidities also is common in this population and may increase the potential for drug-drug interactions (DDIs). METHOD: This review summarizes the multiple factors that may contribute to the therapeutic burden of patients with CRPC, including the interplay between age, comorbidities, concomitant medications, the use of ARIs, and financial distress. CONCLUSIONS: As the treatment landscape in PC continues to rapidly evolve, consideration must be given to the balance between therapeutic benefits and potential treatment-emergent adverse events that may be further complicated by DDIs with concomitant medications. Patient-centered communication is a crucial aspect of alleviating this burden, and healthcare professionals (HCPs) may benefit from training in effective patient communication. HCPs should closely and frequently monitor patient treatment responses, in order to better understand symptom onset and exacerbation. Patients also should be encouraged to participate in exercise programs, and health information and support groups, which may assist them in preventing or mitigating certain determinants of the therapeutic burden associated with PC and its management.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Spratt DE, Shore N, Sartor O, et al. Treating the patient and not just the cancer: therapeutic burden in prostate cancer. Prostate Cancer Prostatic Dis. 2021. PMID: 33603236. doi:10.1038/s41391-021-00328-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。